News & Updates

Patients on sodium-glucose co-transporter (SGLT) 2 inhibitors are less likely to develop asthma compared with those on dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), a study has found.

New data presented at EADV 2021 support the efficacy of secukinumab 300-mg dose in a 2-mL autoinjector compared with two 150 mg in 1 mL pre-filled syringes or placebo for psoriasis, with no new safety signals observed within 52 weeks.

An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.

The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.

Among systemic lupus erythematosus patients, SARS-CoV-2-specific immune responses after BNT162b2 vaccination seem to be impaired in the presence of poor baseline humoral immune status, low naïve B cell frequencies, and mycophenolate mofetil (MMF) and methotrexate (MTX) use, according to a study.

Angiotensin converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) appear to be beneficial to chronic obstructive pulmonary disease (COPD) patients, with a recent study suggesting that the use of such drugs may slow down progression of emphysema and lung function decline.